BRIEF-Cellectar Biosciences Provides Strategic Update On Clinical Development, Pipeline Programs And Corporate Restructuring

Reuters12-11

Dec 10 (Reuters) - Cellectar Biosciences Inc CLRB.O:

CELLECTAR BIOSCIENCES PROVIDES STRATEGIC UPDATE ON CLINICAL DEVELOPMENT, PIPELINE PROGRAMS AND CORPORATE RESTRUCTURING
CELLECTAR BIOSCIENCES INC - TO PURSUE STRATEGIC OPTIONS FOR IOPFOSINE I 131 DEVELOPMENT
CELLECTAR BIOSCIENCES INC - TO REDUCE HEADCOUNT BY APPROXIMATELY 60% BY END OF Q4 2024
CELLECTAR BIOSCIENCES INC - TO ADVANCE CLR 121225 AND CLR 121125 INTO CLINIC
CELLECTAR BIOSCIENCES INC - RESTRUCTURING TO EXTEND CASH RUNWAY INTO Q3 2025

Source text: nGNX3KNZMH

Further company coverage: CLRB.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490382022?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-11 06:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490382022","market":"us","top_or_hot":-1,"title":"BRIEF-Cellectar Biosciences Provides Strategic Update On Clinical Development, Pipeline Programs And Corporate Restructuring","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Cellectar Biosciences Provides Strategic Update On Clinical Development, Pipeline Programs And Corporate Restructuring</title></head><body><p><span>Dec 10 (Reuters)</span><span> - </span>Cellectar Biosciences Inc <span>CLRB.O</span>:</p><ul><li><p>CELLECTAR BIOSCIENCES PROVIDES STRATEGIC UPDATE ON CLINICAL DEVELOPMENT, PIPELINE PROGRAMS AND CORPORATE RESTRUCTURING</p></li><li><p>CELLECTAR BIOSCIENCES INC - TO PURSUE STRATEGIC OPTIONS FOR IOPFOSINE I 131 DEVELOPMENT</p></li><li><p>CELLECTAR BIOSCIENCES INC - TO REDUCE HEADCOUNT BY APPROXIMATELY 60% BY END OF Q4 2024</p></li><li><p>CELLECTAR BIOSCIENCES INC - TO ADVANCE CLR 121225 AND CLR 121125 INTO CLINIC</p></li><li><p>CELLECTAR BIOSCIENCES INC - RESTRUCTURING TO EXTEND CASH RUNWAY INTO Q3 2025</p></li></ul><p>Source text: <span>nGNX3KNZMH</span></p><p>Further company coverage: <span>CLRB.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Cellectar Biosciences Provides Strategic Update On Clinical Development, Pipeline Programs And Corporate Restructuring</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Cellectar Biosciences Provides Strategic Update On Clinical Development, Pipeline Programs And Corporate Restructuring\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-11 06:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241210:nTUA2BKQPF:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRIEF-Cellectar Biosciences Provides Strategic Update On Clinical Development, Pipeline Programs And Corporate RestructuringDec 10 (Reuters) - Cellectar Biosciences Inc CLRB.O:CELLECTAR BIOSCIENCES ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241210:nTUA2BKQPF:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241210:nTUA2BKQPF:1","article_id":"2490382022","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490382022","pubTimestamp":1733868060,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Cellectar Biosciences Provides Strategic Update On Clinical Development, Pipeline Programs And Corporate RestructuringDec 10 (Reuters) - Cellectar Biosciences Inc CLRB.O:CELLECTAR BIOSCIENCES PR","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CLRB":"Cellectar Biosciences Inc."},"translate_title":"简介-Cellectar Biosciences提供有关临床开发、管道项目和公司重组的战略更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLRB":0.9},"content_text":"BRIEF-Cellectar Biosciences Provides Strategic Update On Clinical Development, Pipeline Programs And Corporate RestructuringDec 10 (Reuters) - Cellectar Biosciences Inc CLRB.O:CELLECTAR BIOSCIENCES PROVIDES STRATEGIC UPDATE ON CLINICAL DEVELOPMENT, PIPELINE PROGRAMS AND CORPORATE RESTRUCTURINGCELLECTAR BIOSCIENCES INC - TO PURSUE STRATEGIC OPTIONS FOR IOPFOSINE I 131 DEVELOPMENTCELLECTAR BIOSCIENCES INC - TO REDUCE HEADCOUNT BY APPROXIMATELY 60% BY END OF Q4 2024CELLECTAR BIOSCIENCES INC - TO ADVANCE CLR 121225 AND CLR 121125 INTO CLINICCELLECTAR BIOSCIENCES INC - RESTRUCTURING TO EXTEND CASH RUNWAY INTO Q3 2025Source text: nGNX3KNZMHFurther company coverage: CLRB.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"corporation,event","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490382022"}